Dicerna Pharmaceuticals (Cambridge, MA) a development-stage biopharmaceutical company focused on the development RNAi-based therapeutics, closed a $25M Series B financing. Participants include Domain Associates, Oxford Bioscience Partners, Abingworth Management and Skyline Ventures.